NovAliX and Chemical.AI announce drug discovery collaboration
pharmafile | January 25, 2021 | News story | Sales and Marketing | Chemical.AI, Novalix
NovAliX, a drug discovery-focused contract research organisation, and Chemical.AI, an artificial intelligence (AI) company, have announced a strategic collaboration in AI applied to drug discovery.
NovAliX’s 20 years of industry experience, combined with Chemical.AI’s innovations in artificial intelligence, will enable the partners to jointly develop an AI toolkit for drug discovery. The advanced toolkit will be integrated into NovAliX’s drug discovery services whilst commercial release will be available at Chemical.AI.
Through the collaboration, NovAliX will have access to a customised and enhanced AI toolkit ahead of the market, while Chemical.AI will be able to rely on NovAliX’s experienced scientists and unique in-house, high-quality data to develop the most relevant AI tools. The first joint programme focuses on enhancing Chemical.AI’s Computer-Aided Synthesis Planning (CASP) system to be at the forefront of the industry for next-generation predictive retrosynthesis.
Ning Xia, CEO of Chemical.AI, commented: “The decision to collaborate with NovAliX was a natural move for us.
“First, we wanted to team up with scientists who need to solve very complex synthetic challenges. Second, we were seeking exposure to scientists who embrace the variety of preclinical drug discovery projects that enhance the development of the relevant AI solutions for the pharmaceutical industry.”
Denis Zeyer, CEO of NovAliX, also said: “We are thrilled to collaborate with Chemical.AI at this significant and impactful time for us. With this collaboration, NovAliX and Chemical.AI have launched a research programme aimed at demonstrating the performance of Chemical.AI’s CASP system.
“As a result of this teamwork, NovAliX clients will benefit from cutting-edge AI solutions for their research projects. For example, the most advanced version of Chemical.AI’s CASP is already used by NovAliX chemists in discovery chemistry and process research services.”
Darcy Jimenez
